Efficacy of oats in dyslipidemia: a systematic review and meta-analysis

被引:0
|
作者
Li, Anqi [1 ]
Gao, Jing [1 ,2 ]
Li, Yingcai [3 ]
Qi, Shihao [1 ,2 ]
Meng, Tiantian [7 ]
Yu, Shanshan [4 ]
Zhang, Yuqing [5 ,6 ]
He, Qingyong [1 ]
机构
[1] China Acad Chinese Med Sci, Guangan Men Hosp, 5 Bixiange St, Beijing 100051, Peoples R China
[2] Beijing Univ Chinese Med, Beijing, Peoples R China
[3] Bur Agr & Rural Affairs, Yulong Naxi, Yunnan, Peoples R China
[4] Henan Univ Chinese Med, Grad Sch, Zhengzhou, Henan, Peoples R China
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Dept Clin Epidemiol & Biostat, HSC 2C,1200 Main St West, Hamilton, ON L8N 3Z5, Canada
[6] China Acad Chinese Med Sci, Guanganmen Hosp, CEBIM Ctr Evidence Based Integrat Med Clarity Coll, Beijing, Peoples R China
[7] Beijing Univ Chinese Med, Dongfang Hosp, Dept Rehabil, Beijing, Peoples R China
关键词
DENSITY-LIPOPROTEIN CHOLESTEROL; BETA-GLUCAN; SERUM-LIPIDS; CARDIOVASCULAR-DISEASE; WHOLE-GRAIN; GLUCOSE; BRAN; CONSUMPTION; MANAGEMENT; PROFILE;
D O I
10.1039/d3fo04394k
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: In recent years, oats' effect on lowering serum cholesterol has been recognized. However, no systematic reviews summarized the effect of daily consumption of oat-based products on serum lipids in patients with dyslipidemia. Methods: We searched eight databases and two clinical trial registries from inception to July 31, 2023. We included randomized controlled trials (RCTs) evaluating the efficacy of oat-based products (>= 4 weeks) on lipid levels or cardiovascular events in patients with dyslipidemia. Two authors independently screened articles, extracted data and assessed the risk of bias of included studies with Cochrane risk-of-bias tool 2.0. We used STATA 17.0 to conduct meta-analysis and Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. Results: We finally included 17 eligible trials with 1731 subjects. The oat intervention varied from oat beta-glucan-based products to oat bran-based products and wholegrain oat. Overall, the risk of bias of included trials was high or some concerns were noted because of the inadequate randomization, allocation concealment, and inappropriate data analysis method. Compared to the placebo or usual diet, one study indicated that oat-based products have no significant difference in major cardiovascular events. Pooled estimates showed that oat-based products may result in a large reduction in LDL-C (WMD, -0.24 mmol L-1; 95% CI: -0.33, -0.15) (moderate certainty) and TC (WMD, -0.32 mmol L-1; 95% CI: -0.48, -0.17) (moderate certainty). Compared to other diets (mainly other cereals), oat-based products probably reduce the level of LDL-C (WMD, -0.17 mmol L-1; 95% CI: -0.25, -0.08) (moderate certainty) and TC (WMD, -0.21 mmol L-1; 95% CI: -0.30, -0.12) (moderate certainty). Both groups showed that oat-based products had little effect on HDL-C and TG (moderate certainty). Oat-related adverse events were mostly gastrointestinal such as diarrhea, nausea, and flatulence being the most prevalent. Conclusions: Oat-based products may reduce TC and LDL-C, but have little effect on TG, HDL-C, and major cardiovascular events in patients with dyslipidemia. Background: In recent years, oats' effect on lowering serum cholesterol has been recognized.
引用
收藏
页码:3232 / 3245
页数:14
相关论文
共 50 条
  • [1] Efficacy of oats for dyslipidaemia: protocol for a systematic review and meta-analysis
    Li, Anqi
    Li, Min
    Guo, Jianbo
    Yun, Wingyan
    He, Qingyong
    BMJ OPEN, 2022, 12 (04):
  • [2] Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
    Ida, Satoshi
    Kaneko, Ryutaro
    Murata, Kazuya
    CARDIOVASCULAR DIABETOLOGY, 2019, 18
  • [3] Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
    Satoshi Ida
    Ryutaro Kaneko
    Kazuya Murata
    Cardiovascular Diabetology, 18
  • [4] Dyslipidemia in Muscular Dystrophy: A Systematic Review and Meta-Analysis
    Sun, Zeren
    Wang, Xindi
    White, Zoe
    Dormuth, Colin
    Morales, Fernando
    Bernatchez, Pascal
    JOURNAL OF NEUROMUSCULAR DISEASES, 2023, 10 (04) : 505 - 516
  • [5] Determinants of Dyslipidemia in Africa: A Systematic Review and Meta-Analysis
    Obsa, Mohammed S.
    Ataro, Getu
    Awoke, Nefsu
    Jemal, Bedru
    Tilahun, Tamiru
    Ayalew, Nugusu
    Woldegeorgis, Beshada Z.
    Azeze, Gedion A.
    Haji, Yusuf
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8
  • [6] A Systematic Review and Meta-Analysis of Food Insecurity and Dyslipidemia
    Arenas, Daniel J.
    Beltr, Sourik
    Montgomery, Canada
    Pharel, Marissa
    Lopez-Hinojosa, Itzel
    Vila-Arroyo, Gilberto
    DeLisser, Horace M.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2022, 35 (04) : 656 - 667
  • [7] Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies
    Chhabra, Manik
    Vidyasagar, Kota
    Gudi, Sai Krishna
    Sharma, Jatin
    Sharma, Rishabh
    Rashid, Muhammed
    PLOS ONE, 2022, 17 (07):
  • [8] Dyslipidemia and Diabetic Macular Edema A Systematic Review and Meta-Analysis
    Das, Radha
    Kerr, Rebecca
    Chakravarthy, Usha
    Hogg, Ruth E.
    OPHTHALMOLOGY, 2015, 122 (09) : 1820 - 1827
  • [9] Prevalence of Dyslipidemia in Iran: A Systematic Review and Meta-Analysis Study
    Tabatabaei-Malazy, Ozra
    Qorbani, Mostafa
    Samavat, Tahereh
    Sharifi, Farshad
    Larijani, Bagher
    Fakhrzadeh, Hossein
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2014, 5 (04) : 373 - 393
  • [10] EFFICACY OF ELAFIBRANOR IN PATIENTS WITH DYSLIPIDEMIA AND NON-ALCOHOLIC STEATOHEPATITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Malik, Adnan
    Nadeem, Mahum
    Haider, Maryam
    Amjad, Waseem
    HEPATOLOGY, 2021, 74 : 1137A - 1137A